免疫核對點抑制劑及其相關不良反應和處理

Managing the Adverse Effects Related to Immune Checkpoint Inhibitors

郭曉萱(Hsiao-Hsuan KUO) ； 陳偉武(Wei-Wu CHEN)

《護理雜誌》 65卷3期 (2018/06) Pp. 88-95

https://doi.org/10.6224/JN.201806_65(3).12

摘要

免疫核對點抑制劑為近年來癌症治療的新趨勢，針對細胞毒性T淋巴細胞相關抗原-4（cytotoxic T- lymphocyte-associated antigen 4, CTLA-4）及程序性細胞死亡1（programmed cell death-1, PD-1）核對點的抑制劑，如ipilimumab（Yervoy®，益伏）、pembrolizumab（Keytruda®，吉舒達）和nivolumab（Opdivo®，保疾伏）被用來提升病患T細胞的活性及毒殺腫瘤的能力，以達到抗癌的效果。這些藥物各有不同的使用建議劑量及調配方法必須注意，此外，這些免疫核對點抑制劑可能會引發皮膚、腸胃道、肝臟、內分泌、肺部及一些罕見但嚴重的免疫相關不良反應，臨床醫療護理人員必須熟悉早期徵象和評估及了解相關處理方式。

關鍵字

免疫核對點抑制劑 ； 免疫相關不良反應

並列摘要

Immune checkpoint inhibitors (ICIs) have become the new posterchild of cancer treatment in recent years largely due to their impressive clinical efficacy. Drugs targeting cytotoxic T- lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death-1 (PD-1) antibodies, e.g., ipilimumab (Yervoy®), pembrolizumab (Keytruda®), and nivolumab (Opdivo®) reinvigorate cytotoxic T cells to kill cancer cells in patients. Despite the impressive clinical benefits, ICIs may induce immune-related adverse events (irAE) of the skin, gastrointestinal tract, liver, endocrine, and lung with a wide spectrum of severity. Rare but severe irAEs of critical organs such as the heart and central nervous system have also been reported. Clinical practitioners must recognize the early signs and symptoms of irAE as well as related management strategies.

並列關鍵字

immune checkpoint inhibitors ； immune-related adverse effect

參考文獻

Bernardo, S. G., Moskalenko, M., Pan, M., Shah, S., Sidhu, H. K., Sicular, S., ... Saenger, Y. M. (2013). Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma. Melanoma Research, 23(1), 47–54. https://doi.org/10.1097/CMR.0b013e32835c7e68

Champiat, S., Lambotte, O., Barreau, E., Belkhir, R., Berdelou, A., Carbonnel, F., ... Marabelle, A. (2016). Management of immune checkpoint blockade dysimmune toxicities: A collaborative position paper. Annals of Oncology, 27(4), 559–574. https://doi.org/10.1093/annonc/mdv623

Dadu, R., Zobniw, C., & Diab, A. (2016). Managing adverse events with immune checkpoint agents. The Cancer Journal, 22(2), 121–129. https://doi.org/10.1097/PPO.0000000000000186

Economopoulou, P., Kotsantis, I., & Psyrri, A. (2016). Checkpoint inhibitors in head and neck cancer: Rationale, clinical activity, and potential biomarkers. Current Treatment Options in Oncology, 17, article 40. https://doi.org/10.1007/s11864-016-0419-z

Friedman, C. F., Proverbs-Singh, T. A., & Postow, M. A. (2016). Treatment of the immune-related adverse effects of immune checkpoint inhibitors. JAMA Oncology, 2(10), 1346–1353. https://doi.org/10.1001/jamaoncol.2016.1051